Review Article
Outcome Reporting Variability in Trials of Chinese Medicine for Hyperlipidemia: A Systematic Review for Developing a Core Outcome Set
Table 2
The ten most frequently reported outcomes among the 3,702 included studies.
| | Outcome name | Domain | No. of studies reported/total (%) | No. of studies reported as primary outcome/total (%) | No. of studies reported as secondary outcome/total (%) | No. of studies reported with definition/total (%) |
| | TG | II. Pathological or pathophysiological | 3211/3702 (86.7%) | 94/3211 (2.9%) | 12/3211 (0.4%) | 73/3211 (2.3%) |
| | TC | II. Pathological or pathophysiological | 3185/3702 (86.0%) | 74/3185 (2.3%) | 14/3185 (0.4%) | 72/3185 (2.3%) |
| | Total effective rate | V. Response rate | 2780/3702 (75.1%) | 18/2780 (0.6%) | 6/2780 (0.2%) | 2648/2780 (95.3%) |
| | HDL-C | II. Pathological or pathophysiological | 2709/3702 (73.2%) | 63/2709 (2.3%) | 17/2709 (0.6%) | 63/2709 (2.3%) |
| | LDL-C | II. Pathological or pathophysiological | 2240/3702 (60.5%) | 79/2240 (3.5%) | 9/2240 (0.4%) | 51/2240 (2.3%) |
| | Liver function | III. Adverse event or safety | 1199/3702 (32.4%) | 1/1199 (0.1%) | 6/1199 (0.5%) | 10/1199 (0.8%) |
| | Renal function | III. Adverse event or safety | 1046/3702 (28.3%) | 1/1046 (0.1%) | 6/1046 (0.6%) | 10/1046 (1.0%) |
| | Blood routine examination | III. Adverse event or safety | 958/3702 (25.9%) | 1/958 (0.1%) | 5/958 (0.5%) | 9/958 (0.9%) |
| | Urine routine examination | III. Adverse event or safety | 873/3702 (23.6%) | 1/873 (0.1%) | 5/873 (0.6%) | 7/873 (0.8%) |
| | ECG | II. Pathological or pathophysiological | 565/3702 (15.3%) | 0/565 (0.0%) | 3/565 (0.5%) | 7/565 (1.2%) |
|
|
TG: total triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ECG: electrocardiogram.
|
